Soft Tissue Sarcoma - Pipeline Insight, 2021
This report can be delivered to the clients within 2-3 Business Days
DelveInsight’s, “Soft Tissue Sarcoma - Pipeline Insight, 2021,” report provides comprehensive insights about 130+ companies and 130+ pipeline drugs in Soft Tissue Sarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Soft Tissue Sarcoma: Overview
Soft-tissue sarcoma (STS) are rare neoplasms that can develop in supporting or connective tissue, such as the muscle, nerves, tendons, blood vessels and fatty and fibrous tissues. They commonly affect the arms, legs, and trunk. They also appear in the stomach and intestines (GIST) as well as behind the abdomen (retroperitoneal sarcomas) and the female reproductive system (gynecological sarcomas). STSs may be classified according to the involved cell-type, the specific nature of the malignancy, and the disease’s clinical course. According to the World Health Organization (WHO), there are more than 50 histologic subtypes of STSs. The signs and symptoms of STSs vary greatly from patients to patients based on the type of STS. However, it is not associated with any noticeable symptoms early in the course of the disease but the affected individuals may notice slow-growing, painless mass in the affected area.
'Soft Tissue Sarcoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Soft Tissue Sarcoma pipeline landscape is provided which includes the disease overview and Soft Tissue Sarcoma treatment guidelines. The assessment part of the report embraces, in depth Soft Tissue Sarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Soft Tissue Sarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Soft Tissue Sarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Soft Tissue Sarcoma Emerging Drugs
Further product details are provided in the report……..
Soft Tissue Sarcoma: Therapeutic Assessment
This segment of the report provides insights about the different Soft Tissue Sarcoma drugs segregated based on following parameters that define the scope of the report, such as:
Soft Tissue Sarcoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Soft Tissue Sarcoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Soft Tissue Sarcoma drugs.
Soft Tissue Sarcoma Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Soft Tissue Sarcoma - Pipeline Insight, 2021,” report provides comprehensive insights about 130+ companies and 130+ pipeline drugs in Soft Tissue Sarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Soft Tissue Sarcoma: Overview
Soft-tissue sarcoma (STS) are rare neoplasms that can develop in supporting or connective tissue, such as the muscle, nerves, tendons, blood vessels and fatty and fibrous tissues. They commonly affect the arms, legs, and trunk. They also appear in the stomach and intestines (GIST) as well as behind the abdomen (retroperitoneal sarcomas) and the female reproductive system (gynecological sarcomas). STSs may be classified according to the involved cell-type, the specific nature of the malignancy, and the disease’s clinical course. According to the World Health Organization (WHO), there are more than 50 histologic subtypes of STSs. The signs and symptoms of STSs vary greatly from patients to patients based on the type of STS. However, it is not associated with any noticeable symptoms early in the course of the disease but the affected individuals may notice slow-growing, painless mass in the affected area.
'Soft Tissue Sarcoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Soft Tissue Sarcoma pipeline landscape is provided which includes the disease overview and Soft Tissue Sarcoma treatment guidelines. The assessment part of the report embraces, in depth Soft Tissue Sarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Soft Tissue Sarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Soft Tissue Sarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Soft Tissue Sarcoma.
This segment of the Soft Tissue Sarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Soft Tissue Sarcoma Emerging Drugs
- AL3818: Advenchen Laboratories
- L19 TNF: Philogen
- NBTXR3: Nanobiotix
- GPX-150: Monopar Therapeutics
- LTX-315: Lytix Biopharma
- Nivolumab: Bristol Myers Squibb
- Lenvatinib: Merck sharp & Dohme Corp.
- Durvalumab: AstraZeneca
- Nintedanib: Boehringer Ingelheim
Further product details are provided in the report……..
Soft Tissue Sarcoma: Therapeutic Assessment
This segment of the report provides insights about the different Soft Tissue Sarcoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Soft Tissue Sarcoma
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intra-arterial
- Intradermal
- Intralesional
- Intratumoral
- Intravenous
- Oral
- Parenteral
- Subcutaneous
- Molecule Type
- Antibody
- Antibody–drug conjugate
- Cell therapy
- Gene therapy
- Immunotherapy
- Nanoparticle
- Peptide
- Recombinant fusion protein
- Small molecule
- Product Type
Soft Tissue Sarcoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Soft Tissue Sarcoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Soft Tissue Sarcoma drugs.
Soft Tissue Sarcoma Report Insights
- Soft Tissue Sarcoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Soft Tissue Sarcoma drugs?
- How many Soft Tissue Sarcoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Soft Tissue Sarcoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Soft Tissue Sarcoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Soft Tissue Sarcoma and their status?
- What are the key designations that have been granted to the emerging drugs?
- Advenchen Laboratories
- Philogen
- Gradalis
- Epizyme
- Eli Lilly and Company
- Chugai Pharma France
- CytRx
- AROG Pharmaceuticals
- Taiho Pharmaceuticals
- NantCell
- KaryoPharm Therapeutics
- Nanobiotix
- Apexigen
- Gem Pharmaceuticals
- Lytix Biopharma
- Novartis
- Athenex
- Bristol Myers Squibb
- Merck Sharp & Dohme
- Bristol Myers Squibb
- Incyte Corporation
- Daiichi Sankyo
- AstraZeneca
- Pfizer
- Merck Sharp & Dohme
- NantPharma
- Iovance Biotherapeutics
- Agenus
- Eli Lilly and company
- AstraZeneca
- Adaptimmune
- Aadi
- Jiangsu HengRui Medicine
- Bayer
- Merck
- GlaxoSmithKline
- AVEO Pharmaceuticals
- Amgen
- Atara Biotherapeutics
- Roche
- Bayer
- VasGene Therapeutics
- Mirati Therapeutics
- EMD Serono
- AGC Biologics
- Novartis
- Genor Biopharma
- Clovis Oncology
- PharmaMar
- Boehringer Ingelheim
- Morphotek (Eisai)
- GlaxoSmithKline
- Novartis
- Incyte Corporation
- Tracon Pharmaceuticals
- Jiangsu Hengrui Medicine
- Exelixis
- Sanofi
- Pfizer
- Merck KGaA
- Roche Pharma AG
- Bristol-Myers Squibb
- Bristol-Myers Squibb
- MedImmune
- Qbiotics
- AstraZeneca
- Novartis
- AstraZeneca
- Aadi
- Loxo Oncology
- AL-3818
- Onfekafusp alfa
- Vigil
- Tazemetostat
- Olaratumab
- Doxorubicin
- Aldoxorubicin
- Crenolanib
- TAS-116
- Ganitumab
- Selinexor
- NBTXR3
- APX005M
- GPX-150
- LTX-315
- PDR001
- Oraxol
- Nivolumab
- Lenvatinib
- Ipilimumab
- INCMGA00012
- Efatutazone
- Durvalumab
- Crizotinib
- MK3475
- AMG337
- LN-145-S1
- AGEN2034
- Abemaciclib
- Olaparib + Trabectedin
- ADP-A2M4
- ABI-009
- Apatinib Mesylate
- Sorafenib Tosylate
- Temozolomide
- TSR-042
- Tivozanib
- Talimogene laherparepvec
- Tabelecleucel
- Bevacizumab
- Regorafenib
- sEphB4-HAS
- Sitravatinib
- M6620
- NGR-hTNF
- Letrozole
- GB226
- Rucaparib
- PM01183
- Nintedanib
- MORAb-004
- NY-ESO-1????T Cells
- Everolimus
- Epacadostat
- Envafolimab
- Camrelizumab
- cabozantinib
- Cabazitaxel
- Axitinib
- Avelumab
- Atezolizumab
- Relatlimab
- Dasatinib
- Tremelimumab
- Tigilanol tiglate
- Selumetinib
- Gemcitabine
- Cediranib
- Nab-rapamycin
- LOXO- 292
Introduction
Executive Summary
Soft Tissue Sarcoma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
L19-TNF: Philogen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Durvalumab: AstraZeneca
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
TBI-1301: Takara Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CEB-01: Cebiotex
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
HSB-114: Hillstream BioPharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Soft Tissue Sarcoma Key Companies
Soft Tissue Sarcoma Key Products
Soft Tissue Sarcoma- Unmet Needs
Soft Tissue Sarcoma- Market Drivers and Barriers
Soft Tissue Sarcoma- Future Perspectives and Conclusion
Soft Tissue Sarcoma Analyst Views
Soft Tissue Sarcoma Key Companies
Appendix
Executive Summary
Soft Tissue Sarcoma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
L19-TNF: Philogen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Durvalumab: AstraZeneca
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
TBI-1301: Takara Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CEB-01: Cebiotex
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
HSB-114: Hillstream BioPharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Soft Tissue Sarcoma Key Companies
Soft Tissue Sarcoma Key Products
Soft Tissue Sarcoma- Unmet Needs
Soft Tissue Sarcoma- Market Drivers and Barriers
Soft Tissue Sarcoma- Future Perspectives and Conclusion
Soft Tissue Sarcoma Analyst Views
Soft Tissue Sarcoma Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Soft Tissue Sarcoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Soft Tissue Sarcoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Soft Tissue Sarcoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Soft Tissue Sarcoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products